A scientific breakthrough with immediate clinical impact: Ultra-high-resolution PET imaging supports early detection, clinical decision-making, and neuroscience research
ROTTERDAM, Netherlands, June 12, 2026 /PRNewswire/ -- UZ Leuven and KU Leuven from Leuven, Belgium have introduced the NeuroEXPLORER PET into clinical practice, one of the world's most advanced ultra-high resolution PET scanners delivered by United Imaging Healthcare. The system has been operational for six months and has already supported imaging in over 400 patients. It marks a transformative milestone in molecular brain and head & neck imaging, enabling visualization of structures and circuits in patients at near-millimetre resolution that were previously inaccessible in living patients.
Early Detection and Precision Diagnosis
Working with the NeuroEXPLORER PET enables researchers and clinicians to identify disease processes at the very earliest stages of disease, particularly in neurodegenerative diseases such as Alzheimer's, Parkinson's and ALS. By detecting the effects of key chemical signals associated with these diseases, the system enables earlier and more precise diagnosis, as well as the detection of very small abnormalities, including brain tumours. According to Koen Van Laere, Professor of Nuclear Medicine and Principal Investigator: "This technology fundamentally changes how we can investigate the origins and diagnoses of neurological and psychiatric diseases, as well as vascular diseases and head- and neck disorders such as tumours. It allows us to measure disease processes in very small structures with unprecedented precision."
Clinical and research applications
The scanner contributes to both fundamental and prospective clinical research programs, including:
The system enables very precise localisation and quantification of key biological processes in the brain, including synaptic density, tau and amyloid accumulation, dopaminergic and noradrenergic systems in small brain stem nuclei, microglial activation in neuroinflammation, and metabolic brain connectivity. Comparative studies with standard-of-care imaging already indicate improved individual treatment decisions.
Advancing neurosurgical precision
For neurosurgical procedures such as the treatment of small pituitary tumours and deep brain stimulation, precise targeting is critical. Thomas Decramer, neurosurgeon at UZ Leuven, said: "Ultra-high resolution imaging improves our ability to define optimal resection of microtumours in the pituitary that overproduce certain hormones, and also improves the placement of electrodes for neurostimulation. This has direct implications for successful surgical outcomes and for rendering patients disease free in cases of pituitary tumours." The combination of very high sensitivity and ultra-high spatial resolution supports applications ranging from neurodegenerative diseases and epilepsy to vascular disorders and neuroinflammation, expanding opportunities for both clinical investigation and patient care.
Expanding opportunities for research and collaboration
Mathieu Vandenbulcke, Chair of the Leuven Brain Institute, said: "The NeuroEXPLORER strengthens Leuven's international position in brain research and precision medicine. It creates a unique platform for global scientific collaboration."
Over the next five years, the scanner will support more than thirty large-scale research programs across neurodegeneration, psychiatry, epilepsy, neuromodulation, inflammation and oncology. Among them are studies investigating brain stem nuclei affected in the earliest stages of Alzheimer's disease, with the aim of improving understanding of disease progression and supporting more personalised treatment approaches.
For more information
About KU Leuven
KU Leuven is Europe's most innovative university (Reuters) and ranks 43rd in the Times Higher Education World University Rankings. As Belgium's largest university, KU Leuven welcomes 65,000 students from over 140 countries. The University's more than 8,000 researchers are active in a comprehensive range of disciplines. KU Leuven is a founding member of the League of European Research Universities (LERU) and has a strong European and international orientation. University Hospitals Leuven, its network of research hospitals, provides high-quality healthcare and develops new therapeutic and diagnostic insights with an emphasis on translational research.
Read more: www.kuleuven.be/english/kuleuven/
About UZ Leuven
As Belgium's largest university hospital, UZ Leuven wants to push boundaries by combining specialised care and innovative treatment with humane attention and respect for every patient. Every day, almost 10.000 passionate employees provide the best customised care possible. At UZ Leuven, future care providers and employees are guaranteed high-quality training, with a view to life-long learning and innovation. As a pioneer in clinical research, the hospital also contributes to future patient care.
Read more: https://www.uzleuven.be/en/about-us
About United Imaging Healthcare
United Imaging Healthcare is a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, with native AI embedded across their portfolio to deliver real clinical impact at scale. The company develops advanced imaging, radiotherapy and digital technologies designed to support clinical decision making and expand access to high quality care worldwide. This includes state-of-the-art solutions for Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Molecular Imaging (PET/CT and PET/MR), Digital Radiography (including mammography and mobile C-arm solutions), as well as advanced medical imaging software. To learn more, visit United-Imaging: United Medical Imaging Healthcare Innovator or follow United Imaging Healthcare Europe on LinkedIn.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/uz-and-ku-leuven-neuroexplorer-pet-makes-detection-of-early-phases-of-diseases-possible-302798990.html
Cham Swiss Properties AG hat den nächsten Schritt zur vollständigen Übernahme der Bredella Beteiligungen AG vollzogen. Das in Cham (ZG) ansässige Immobilienunternehmen schuf im Rahmen einer Kapitalerhöhung 1'427'668 neue Namenaktien aus dem bestehenden Kapitalband, die inzwischen im Handelsregister eingetragen sind. Hintergrund ist eine am 4. Juni 2026 angekündigte Transaktion, mit der Cham Swiss Properties sämtliche Minderheitsanteile an der Bredella Beteiligungen AG im Weg eines Aktientauschs erwerben will.
Mit der Ausgabe der neuen Papiere steigt die Zahl der ausstehenden Namenaktien um 3,0% auf neu 48'906'622. Die Handelszulassung der zusätzlichen Titel an der SIX Swiss Exchange erfolgt am heutigen Tag. Der eigentliche Aktientausch zum Erwerb der verbleibenden Bredella-Anteile soll den Angaben zufolge innerhalb der kommenden zehn Tage abgeschlossen werden.
Cham Swiss Properties war 2025 aus der Fusion der Ina Invest AG und der Cham Group AG hervorgegangen und zählt nach eigenen Angaben zu den Eigentümern eines der hochwertigsten Immobilienportfolios in der Schweiz. Der Fokus liegt auf der Entwicklung von Wohn- und Arbeitsräumen an zentralen Lagen mit guter Anbindung an den öffentlichen Verkehr. Das bestehende Portfolio beläuft sich derzeit auf rund 1,7 Milliarden Schweizer Franken. Nach Fertigstellung der laufenden Projekte rechnet die Gesellschaft mit einem Ausbau der Portfoliogrösse auf etwa 3 Milliarden Franken und jährlichen Mieteinnahmen von über 100 Millionen Franken.
Rund 70 Mitarbeitende decken laut Unternehmen die gesamte Wertschöpfungskette des Immobilienzyklus ab – von der Entwicklung über die Realisierung bis zum Betrieb. Cham Swiss Properties ist an der SIX Swiss Exchange kotiert; die Aktie wird unter dem Tickerkürzel CHAM und der Valorennummer CH0524026959 gehandelt. Mit der nun eingeleiteten vollständigen Integration der Bredella Beteiligungen AG stärkt der Konzern seine Struktur und setzt den eingeschlagenen Wachstumspfad im Schweizer Immobilienmarkt fort.
